SaaS entity
Every one of those 1 sits in a single category, earnings. Atea Pharmaceuticals is most often covered alongside BBOT, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 6 original sources each against 3.9 for the same window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Atea Pharmaceuticals is most often covered alongside BBOT, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 6 original sources each against 3.9 for the same window. Their average consequence score of 5 runs below the beat's 6.6 for that window. We currently track 1 SaaS story that mention Atea Pharmaceuticals, all published on March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 35 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Atea Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Rumble and OptimizeRx reported their fourth-quarter and full-year 2025 financial results, highlighting significant growth in cloud infrastructure and digital health engagement. These results underscore a broader trend of resilient demand for specialized SaaS platforms and independent cloud ecosystems.
Source: manilatimes.net
Atea Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
